This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Amicus Therapeutics' CEO Hosts GSK Expanded Fabry Collaboration Call (Transcript)

Secondly, we have a new division of responsibilities as a result of this extended collaboration. Amicus will now have responsibility for all commercial operations relative to all of these Fabry products – so the monotherapy use of migalastat, the use of migalastat in combination with other existing ERTs as well as the sales and marketing of this future proprietary ERT as it hopefully makes its way through the clinic. And then the third component and further strengthening our relationship with GSK – GSK is increasing its ownership in Amicus to 19.9% and purchasing 2.95 million shares of our common stock at a premium to today’s market close. They’ll be purchasing that at $6.30 for a total investment of a little over $18.5 million.

So those are the three components and I’ll comment just briefly now on the rationale from Amicus’ perspective and some of the history of how this came to be. I’ll take you first to our vision and one that I reiterated earlier this year at the JP Morgan conference, and that’s that Amicus would be a company at the forefront of rare and orphan diseases and very significantly utilizing our core platform technology including the extension of that along a continuum of innovation, taking our molecules from small molecule monotherapy as we already have now in advanced development in Fabry disease; looking for co-administration therapies but also very, very aggressively developing that technology co-formulated with enzyme replacement therapy. And David will share more of the scientific rationale for that.

But it fits very much in with our business-led, science-driven motto here at Amicus, and it is in line, too, with the vision that I articulated and we have continued to articulate throughout this year that our long-term vision in building Amicus is to be fully integrated by a pharmaceutical company in the rare diseases. And with this, this now allows us to begin preparing for the commercial launch of our products in Fabry disease as they hopefully make their way through the clinic, leading of course with our 011 study, our monotherapy study which remains on track for data delivery here in Q3.

Read the rest of this transcript for free on seekingalpha.com

3 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,098.45 +18.88 0.11%
S&P 500 2,003.37 +6.63 0.33%
NASDAQ 4,580.2710 +22.5760 0.50%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs